Ozkaramanli Gur Demet, Baykız Derya, Akyuz Aydin, Alpsoy Seref, Fidan Cigdem
Department of Cardiology, Namik Kemal University Faculty of Medicine, Tekirdag State Hospital, Tekirdag, Turkey. Electronic correspondence:
Department of Biochemistry, Namik Kemal University Faculty of Medicine, Tekirdag State Hospital, Tekirdag, Turkey.
J Heart Valve Dis. 2018 Jan;27(1):55-64.
Despite considerations of its therapeutic range and multiple drug-food interactions, warfarin is the mainstay of oral anticoagulation in patients with mechanical heart valves (MHVs). The quality of anticoagulation demonstrates variations, with 'time in therapeutic range' (TTR) values usually lower than expected. It has been hypothesized that warfarin adherence is among the modifiable causes of suboptimal coagulation. The aim of the study was to demonstrate the ability of the 8-Item Morisky Medication Adherence Scale (MMAS-8©) to identify patients with non-adherence to warfarin, and to define the predictors of optimal coagulation when a TTR value ≥65% is used as the surrogate.
In a cross-sectional survey of 112 patients, TTR6 months and TTR12 months were calculated using the Rosendaal method. A questionnaire was used to assess the patients' warfarin knowledge, bleeding complications, and adherence. Patients were categorized into low-adherence (LA), moderate adherence (MA) and high-adherence (HA) groups based on MMAS-8 values. The target INR was 2.5-3.5, and an effective TTR was defined as ≥65%.
TTR6 months, TTR12 months and warfarin knowledge were significantly lower in the LA group than in the MA and HA groups. In addition, the bleeding score of HA patients was significantly lower than that of LA and MA patients. The MMAS-8 was the single independent predictor of effective TTR for six and 12 months on multivariate regression analysis (B = 0.506, p <0.001 and B = 0.469, p <0.001, respectively).
Warfarin adherence accounted for poor TTR values in patients with MHV, and MMAS-8 was used effectively to identify those expected to have a low TTR, to suffer more complications, and to require robust education.
尽管考虑到华法林的治疗范围及多种药物与食物的相互作用,但它仍是机械心脏瓣膜(MHV)患者口服抗凝治疗的主要药物。抗凝质量存在差异,“治疗范围内时间”(TTR)值通常低于预期。据推测,华法林依从性是导致抗凝效果欠佳的可改变因素之一。本研究的目的是证明8项Morisky药物依从性量表(MMAS - 8©)识别不依从华法林治疗患者的能力,并确定以TTR值≥65%作为替代指标时最佳凝血的预测因素。
在一项对112例患者的横断面调查中,采用Rosendaal法计算6个月TTR和12个月TTR。使用问卷评估患者对华法林的了解情况、出血并发症及依从性。根据MMAS - 8值将患者分为低依从性(LA)、中度依从性(MA)和高依从性(HA)组。目标国际标准化比值(INR)为2.5 - 3.5,有效TTR定义为≥65%。
LA组的6个月TTR、12个月TTR及对华法林的了解程度均显著低于MA组和HA组。此外,HA组患者的出血评分显著低于LA组和MA组患者。多因素回归分析显示,MMAS - 8是6个月和12个月有效TTR的唯一独立预测因素(B = 0.506,p <0.001;B = 0.469,p <0.001)。
华法林依从性是导致MHV患者TTR值不佳的原因,MMAS - 8可有效识别预期TTR值低、并发症更多且需要强化教育的患者。